Sigma-Aldrich Corp (SIAL)

Sigma Aldrich products are trusted dearly in the research community. Over and over again, I see publications that include a named reference for the chemical used and it's Sigma that is referenced. In our lab, when I really care about quality, it is Sigma I turn to.

SIAL is a pretty safe bet. With a beta of 0.76, it is less risky than the market. SIALs financials are much stronger than the industry average, and they have a smart mangement team. Sigma-Aldrich also has a really low debt level. SIAL is a steady performer, and its share prices have moved up at a pretty steady rate. And, though this stock may not have spectacular short-term gains, it is a safe, long-term play. Since it divested its metals division and decided to focus on research chemicals, it has outperformed steadily for the last 6-7 years.

Very underpriced for a high quality health chemical research stock. Their pipeline of antibodies to link to all 22,000 known human proteins will be vital for future research in all fields of medicine.

bio 101 we all need high tech bio materials

Steady business, steady cash flows, steady returns, steady management. Steady as she goes.

Extra $10B for the NIH in the stimulus package; some will end up in SIAL's pockets.

Triple weekly bottom at 35, 14 weeks trading at the 40 level showing zero momentum. Trading between the 9 and 18 weekly moving average. Buy at 40, stop at 38

In a former life, I did a bit of Chemistry. This morning slurping my favourite hot-solvent extracted filtrate (that's coffee people) I saw the symbol SIAL and Sigma Aldrich zip across the CNBC ticker. That's a blast from the past I've seen before and kept meaning to investigate. SIAL trades at a PE of 15 and a yield of 1.4%. It's tied to life sciences and research chemistry. It's chemical catalog is practically an academic reference, any chemist knows if you can't buy it in the Sigma Aldrich catalog, your going to have to hit the cookbooks to figure out how to make it yourself.

I've giving this stock the green thumb today in a difficulty market because my previous life tells me this company is going to be a steady earner whose earnings are going to be fairly solid.

Great Company!!!

Steady dividend, reasonable P/E, retaining it's value well through the downturn, I think they have positive prospects going forward. Recent drop is them being the baby in the bath, I reckon.

lots of insider selling seems to be going on, including the head of R&D. Maybe just taking advantage of the stock being over $60 but too much for my tastes.

This is one of my favorite companies in the biotch support space. I ended a previous pick as raw materials costs were rising, but that trend is reversed and the stock is cheap again. Time to re-up and probably rebuy in reality as well. Overseas growth is still solid as well.

I love sigma for so many reasons. They're expanding nicely into many technology areas and the like. They're the go-to company for all research, and I anticipate continued growth in the research field -- especially if fuel cell and hydrogen storage technology is continually pushed. Their MOF development is great, and they're a powerhouse of application goodness.

The applications of MOFs that require ultra-high surface areas exceeding 2000 m2/g include:

* Hydrogen storage
* Sensors
* Catalysts
* Separation of gases and others

I'm probably overly biased toward the greatness of Sigma because I'm involved in research, but I dunno, they're quite a tasty beast that should do well for some time to come.

part of the mattchenzo 50, picked from the s&p500 on fundamentals, almost sure to outperform!

When a stock gets positive press, it usually does pretty well. On 4/24/08, the Street.com named SIAL one of 5 top midcaps. The company gets the positive buzz for good reason. The company grew 14.9% in Q1 FY08 versus Q1 FY07. Net income increased by 12.8%. In addition, the management has raised their earning forecast for full FY08 by $0.05 per share to $2.57 to $2.67, up 9.8% and 14.1% over FY07. The company is highly efficient, is financially solvent, has improved income and has shown outstanding growth.

Undervalued, target is $66. Has proven products used worldwide as reflected in net income. This stock is holding up well via relative strength over its 3, 6, and 12 month periods.

produces specialty chemicals and kits used in scientific and genomic research, drug development and the diagnosis of disease. It produces more than 100,000 products, operates in three dozen countries and has more than 60,000 government and private-sector customers.

The St. Louis company focuses on finding growth opportunities in the biotech industry. It recently made a strategic investment in a life-sciences venture fund, Prolog Ventures.

Its research biotech unit accounted for 15% of overall sales in 2007, a year in which Sigma-Aldrich topped $2 billion in sales for the first time. Management vowed to continue its annual trend of delivering at least 10% growth in sales and earnings in 2008.

The company sees growth potential in booming Asia-Pacific economies such as India and China, and it's pursuing clients among small- and mid-sized biotech companies, the St. Louis Post-Dispatch reported. Growth in the U.S. market is hobbled by a stagnant federal research budget as well as the struggles of its big pharmaceutical clients.

Nano tube technology

Steady, rapid growth all year. A+